Organoid screening platforms are transforming drug discovery by providing physiologically relevant 3D models that improve ...

This Perspective reviews how AI is moving drug discovery from long, costly experimental pipelines toward earlier clinical ...

The process of discovering new drugs and bringing them to market is notoriously slow and inefficient. Amazon Web Services is ...

In the race of innovative drug R&D, whether for antibodies, peptides, or novel binding proteins, the efficiency of early-stage molecule discovery is always the key factor determining project success ...

Since its founding in 2017, Alloy has collaborated with more than 200 partners across multiple biologic modalities - including antibodies, bispecifics, genetic medicines, and cell therapies - ...

As the AI era becomes increasingly shaped by foundation models, the pharmaceutical industry is entering a new phase of opportunity for discovery, design, and decision-making driven by AI for science.

Structural alterations in the genome, particularly those leading to fusion oncogenes, represent cornerstone events in the biology of both solid and ...

The key insight with a new strategy for training protein engineering models, called EvoRank, is to harness the natural variations of millions of proteins generated by evolution over deep time and ...

Explore emerging screening technologies in drug discovery. Enhance laboratory workflows with advanced models, CRISPR, and ...

Sept 2 (Reuters) - Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results, in line with an FDA push to reduce animal testing in ...

In this Point of View column,, CEO of Taconic Biosciences, explores redefining preclinical models for the future of drug development.

EvoRank offers a new and tangible example of how AI may help bring disruptive change to biomedical research and biotechnology more broadly. Using the MutRank framework trained with EvoRank, Danny Diaz ...